HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

agaricoglyceride A

from the Shaggy Ink Cap Medicinal Mushroom, Coprinus comatus

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Lipids: 114793
- Glycerides: 109
  - agaricoglyceride A: 1

Experts

1.	Abbruscato, Thomas J: 1 article (01/2020)
2.	Al Shoyaib, Abdullah: 1 article (01/2020)
3.	Alamri, Faisal F: 1 article (01/2020)
4.	Arumugam, Thiruma V: 1 article (01/2020)
5.	Chowdhury, Ekram A: 1 article (01/2020)
6.	German, Nadezhda: 1 article (01/2020)
7.	Jayaraman, Srinidhi: 1 article (01/2020)
8.	Karamyan, Vardan T: 1 article (01/2020)
9.	Kocot, Joanna: 1 article (01/2020)
10.	Rashid, Mamoon: 1 article (01/2020)

Related Diseases

1.	Stroke (Strokes) 01/01/2020 - "Administration of a specific Nln inhibitor Agaricoglyceride A (AgaA) to mice after stroke in a middle cerebral artery occlusion model, dose-dependently aggravated injury measured by increased infarct and edema volumes, blood-brain barrier disruption, increased levels of interleukin 6 and monocyte chemoattractant protein-1, neurological and motor deficit 24 h after stroke. "
2.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/01/2020 - "Administration of a specific Nln inhibitor Agaricoglyceride A (AgaA) to mice after stroke in a middle cerebral artery occlusion model, dose-dependently aggravated injury measured by increased infarct and edema volumes, blood-brain barrier disruption, increased levels of interleukin 6 and monocyte chemoattractant protein-1, neurological and motor deficit 24 h after stroke. "
3.	Infarction (Infarctions) 01/01/2020 - "Administration of a specific Nln inhibitor Agaricoglyceride A (AgaA) to mice after stroke in a middle cerebral artery occlusion model, dose-dependently aggravated injury measured by increased infarct and edema volumes, blood-brain barrier disruption, increased levels of interleukin 6 and monocyte chemoattractant protein-1, neurological and motor deficit 24 h after stroke. "
4.	Edema (Dropsy) 01/01/2020 - "Administration of a specific Nln inhibitor Agaricoglyceride A (AgaA) to mice after stroke in a middle cerebral artery occlusion model, dose-dependently aggravated injury measured by increased infarct and edema volumes, blood-brain barrier disruption, increased levels of interleukin 6 and monocyte chemoattractant protein-1, neurological and motor deficit 24 h after stroke. "

Related Drugs and Biologics

1.	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)
2.	Interleukin-6 (Interleukin 6)